FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094672734> ?p ?o ?g. }

• W2094672734 endingPage "953" @default.
• W2094672734 startingPage "944" @default.
• W2094672734 abstract "Renin-angiotensin system inhibitors have renoprotective effects in patients with chronic kidney disease, but most patients treated with these drugs have residual urinary albumin excretion. Some small clinical studies show that mineralocorticoid receptor blockade reduces albuminuria. Our study aimed to examine the beneficial effects of addition of a selective aldosterone antagonist, eplerenone, to renin-angiotensin system inhibitors in hypertensive patients with non-diabetic chronic kidney disease.In this double-blind, randomised, placebo-controlled trial, we enrolled hypertensive patients, aged 20–79 years, with albuminuria (urinary albumin-to-creatinine ratio [UACR] in the first morning void urine of 30–599 mg/g), an estimated glomerular filtration rate of 50 mL/min per 1·73 m2 or more, and who had received an angiotensin-converting enzyme inhibitor, an angiotensin receptor blocker, or both, for at least 8 weeks. Participants were from 59 clinics and hospitals in Japan. Eligible patients were randomly assigned (1:1), stratified by baseline characteristics, to either low-dose eplerenone (50 mg/day) or placebo, with continuation of standard antihypertensive treatment to attain therapeutic goals (<130/80 mm Hg) for 52 weeks. We assessed efficacy in all patients who received allocated treatment, provided a baseline and post-treatment urine sample, and remained in follow-up. We assessed safety in all patients who received allocated treatment. The primary efficacy measure was percent change in UACR in the first morning void urine at week 52 from baseline. The trial is registered at the clinical trials registry of University Hospital Medical Information Network (UMIN), trial identification number UMIN000001803.Between April 1, 2009, and March 31, 2012, we randomly allocated 170 patients to the eplerenone group and 166 patients to the placebo group. In the primary efficacy analysis, mean percent change in UACR from baseline was −17·3% (95% CI −33·65 to −0·94) for 158 patients in the eplerenone group compared with 10·3% (−6·75 to 22·3) for 146 patients in the placebo group (absolute difference −27·6% [–51·15 to −3·96]; p=0·0222). In the safety analyses, 53 (31%) of 169 patients in the eplerenone group had adverse events (five serious), as did 49 (30%) of 163 in the placebo group (seven serious). Although mean serum potassium concentration was higher in the eplerenone group than the placebo group, severe hyperkalaemia (>5·5 mmol/L) was not recorded in either group.Addition of low-dose eplerenone to renin-angiotensin system inhibitors might have renoprotective effects through reduction of albuminuria in hypertensive patients with non-diabetic chronic kidney disease, without serious safety concerns.Pfizer." @default.
• W2094672734 created "2016-06-24" @default.
• W2094672734 creator A5008201708 @default.
• W2094672734 creator A5015086199 @default.
• W2094672734 creator A5016975375 @default.
• W2094672734 creator A5036685729 @default.
• W2094672734 creator A5074167675 @default.
• W2094672734 creator A5080266991 @default.
• W2094672734 date "2014-12-01" @default.
• W2094672734 modified "2023-10-11" @default.
• W2094672734 title "Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial" @default.
• W2094672734 cites W1968999388 @default.
• W2094672734 cites W1977653501 @default.
• W2094672734 cites W1979008376 @default.
• W2094672734 cites W1983539151 @default.
• W2094672734 cites W1984546703 @default.
• W2094672734 cites W2010799694 @default.
• W2094672734 cites W2011400924 @default.
• W2094672734 cites W2017268330 @default.
• W2094672734 cites W2025002298 @default.
• W2094672734 cites W2049103906 @default.
• W2094672734 cites W2050263292 @default.
• W2094672734 cites W2052653818 @default.
• W2094672734 cites W2053567410 @default.
• W2094672734 cites W2056194572 @default.
• W2094672734 cites W2075323044 @default.
• W2094672734 cites W2080843755 @default.
• W2094672734 cites W2101948924 @default.
• W2094672734 cites W2105978370 @default.
• W2094672734 cites W2107319610 @default.
• W2094672734 cites W2118932957 @default.
• W2094672734 cites W2123778248 @default.
• W2094672734 cites W2132715232 @default.
• W2094672734 cites W2141386688 @default.
• W2094672734 cites W2141932120 @default.
• W2094672734 cites W2146071445 @default.
• W2094672734 cites W2152189242 @default.
• W2094672734 cites W2156825907 @default.
• W2094672734 cites W2157734027 @default.
• W2094672734 cites W2162368776 @default.
• W2094672734 cites W2163709605 @default.
• W2094672734 cites W2164322065 @default.
• W2094672734 cites W2170271198 @default.
• W2094672734 cites W2170453602 @default.
• W2094672734 cites W2615684303 @default.
• W2094672734 cites W3156148333 @default.
• W2094672734 doi "https://doi.org/10.1016/s2213-8587(14)70194-9" @default.
• W2094672734 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25466242" @default.
• W2094672734 hasPublicationYear "2014" @default.
• W2094672734 type Work @default.
• W2094672734 sameAs 2094672734 @default.
• W2094672734 citedByCount "87" @default.
• W2094672734 countsByYear W20946727342014 @default.
• W2094672734 countsByYear W20946727342015 @default.
• W2094672734 countsByYear W20946727342016 @default.
• W2094672734 countsByYear W20946727342017 @default.
• W2094672734 countsByYear W20946727342018 @default.
• W2094672734 countsByYear W20946727342019 @default.
• W2094672734 countsByYear W20946727342020 @default.
• W2094672734 countsByYear W20946727342021 @default.
• W2094672734 countsByYear W20946727342022 @default.
• W2094672734 countsByYear W20946727342023 @default.
• W2094672734 crossrefType "journal-article" @default.
• W2094672734 hasAuthorship W2094672734A5008201708 @default.
• W2094672734 hasAuthorship W2094672734A5015086199 @default.
• W2094672734 hasAuthorship W2094672734A5016975375 @default.
• W2094672734 hasAuthorship W2094672734A5036685729 @default.
• W2094672734 hasAuthorship W2094672734A5074167675 @default.
• W2094672734 hasAuthorship W2094672734A5080266991 @default.
• W2094672734 hasConcept C126322002 @default.
• W2094672734 hasConcept C126894567 @default.
• W2094672734 hasConcept C134018914 @default.
• W2094672734 hasConcept C142724271 @default.
• W2094672734 hasConcept C159641895 @default.
• W2094672734 hasConcept C189135053 @default.
• W2094672734 hasConcept C204787440 @default.
• W2094672734 hasConcept C27081682 @default.
• W2094672734 hasConcept C2776174234 @default.
• W2094672734 hasConcept C2776379505 @default.
• W2094672734 hasConcept C2778525890 @default.
• W2094672734 hasConcept C2778653478 @default.
• W2094672734 hasConcept C2780072264 @default.
• W2094672734 hasConcept C2781203188 @default.
• W2094672734 hasConcept C71924100 @default.
• W2094672734 hasConceptScore W2094672734C126322002 @default.
• W2094672734 hasConceptScore W2094672734C126894567 @default.
• W2094672734 hasConceptScore W2094672734C134018914 @default.
• W2094672734 hasConceptScore W2094672734C142724271 @default.
• W2094672734 hasConceptScore W2094672734C159641895 @default.
• W2094672734 hasConceptScore W2094672734C189135053 @default.
• W2094672734 hasConceptScore W2094672734C204787440 @default.
• W2094672734 hasConceptScore W2094672734C27081682 @default.
• W2094672734 hasConceptScore W2094672734C2776174234 @default.
• W2094672734 hasConceptScore W2094672734C2776379505 @default.
• W2094672734 hasConceptScore W2094672734C2778525890 @default.
• W2094672734 hasConceptScore W2094672734C2778653478 @default.
• W2094672734 hasConceptScore W2094672734C2780072264 @default.
• W2094672734 hasConceptScore W2094672734C2781203188 @default.

• next